World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
70
Citations
18428
World Ranking
2408
National Ranking
15

Zelig Eshhar publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Zelig Eshhar sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 228 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Zelig Eshhar D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Zelig Eshhar sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 70 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Zelig Eshhar is affiliated with the Weizmann Institute of Science in Israel and has a research focus spanning medicine and immunology and microbiology. Their publications emphasize the intersection of oncology, immunology, and biomedical engineering, with a particular specialization in CAR-T cell therapy research.

The scientist's work broadly covers the following main fields of study:

  • Medicine
  • Immunology and Microbiology

Subfields include:

  • Oncology
  • Immunology
  • Biomedical Engineering
  • Molecular Biology
  • Radiology, Nuclear Medicine and Imaging

Key topics addressed in their research consist of:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Nanowire Synthesis and Applications
  • Monoclonal and Polyclonal Antibodies Research
  • Viral Infectious Diseases and Gene Expression in Insects
  • 3D Printing in Biomedical Research

Zelig Eshhar has published in several scientific venues, including:

  • Cancer Letters
  • European Journal of Immunology
  • Nature Communications
  • Cancer Immunology Research
  • The Journal of Immunology

Some of their recent papers include:

  • Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies (2020, Cancer Letters)
  • CAR T cells: Building on the CD19 paradigm (2021, European Journal of Immunology)
  • P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas (2021, Nature Communications)
  • Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity (2020, Cancer Immunology Research)
  • T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields (2021, The Journal of Immunology)

Zelig Eshhar has collaborated frequently with other researchers. Regular coauthors include:

  • Anat Globerson Levin
  • Tova Waks
  • Galit Horn
  • Tamar Shiloach
  • Árpád Szöőr

This research record reflects extensive involvement in advancing various dimensions of immunotherapy, CAR-T design, and tumor immunology. The integration of biomedical engineering techniques is evident in their multidisciplinary approach.

Best Publications

  • Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

    Zelig Eshhar;Tova Waks;Gideon Gross;Daniel G. Schindler

  • Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

    Gideon Gross;Tova Waks;Zelig Eshhar

  • A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

    Michael H. Kershaw;Michael H. Kershaw;Michael H. Kershaw;Jennifer A. Westwood;Jennifer A. Westwood;Linda L. Parker;Gang Wang;Gang Wang

  • In Vivo Antitumor Activity of T Cells Redirected with Chimeric Antibody/T-Cell Receptor Genes

    Patrick Hwu;J. C. Yang;R. Cowherd;J. Treisman

  • A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

    Yangbing Zhao;Qiong J. Wang;Shicheng Yang;James N. Kochenderfer

  • Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

    P Hwu;G E Shafer;J Treisman;D G Schindler

  • Detection of a cytokeratin determinant common to diverse epithelial cells by a broadly cross-reacting monoclonal antibody

    O. Gigi;B. Geiger;Z. Eshhar;R. Moll

  • Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells

    Dan Blat;Ehud Zigmond;Ehud Zigmond;Zoya Alteber;Tova Waks

  • Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.

    I Stancovski;D G Schindler;T Waks;Y Yarden

  • Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.

    Alain B. Schreiber;Irit Lax;Yosef Yarden;Zelig Eshhar

  • Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR

    R A Willemsen;M E M Weijtens;C Ronteltap;Z Eshhar

  • Functional expression of chimeric receptor genes in human T cells.

    Zelig Eshhar;Tova Waks;Alain Bendavid;Daniel G Schindler

  • Redirection of Regulatory T Cells With Predetermined Specificity for the Treatment of Experimental Colitis in Mice

    Eran Elinav;Tova Waks;Zelig Eshhar

  • catELISA: a facile general route to catalytic antibodies.

    Dan S. Tawfik;Bernard S. Green;Rachel Chap;Michael Sela

  • Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor

    Eran Elinav;Nitzan Adam;Tova Waks;Zelig Eshhar

  • Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE.

    Michal Baniyash;Zelig Eshhar

  • Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity.

    G Gross;G Gorochov;T Waks;Z Eshhar

  • Tumor-specific T-bodies: towards clinical application

    Zelig Eshhar

  • Chimeric receptor genes and cells transformed therewith

    Zelig Eshhar;Daniel Schindler;Tova Waks;Gideon Gross

  • Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

    Gideon Gross;Gideon Gross;Zelig Eshhar;Zelig Eshhar

  • Lymphoid cell surface interaction structures detected using cytolysis-inhibiting monoclonal antibodies.

    Pierre Golstein;Christo Goridis;Anne-Marie Schmitt-Verhulst;Brigitte Hayot

Frequent Co-Authors

Dan S. Tawfik
Dan S. Tawfik Weizmann Institute of Science
David Wallach
David Wallach Weizmann Institute of Science
Eran Elinav
Eran Elinav Weizmann Institute of Science
Daniela Novick
Daniela Novick Weizmann Institute of Science
Michael Sela
Michael Sela Weizmann Institute of Science
Avi Orr-Urtreger
Avi Orr-Urtreger Tel Aviv University
Menachem Rubinstein
Menachem Rubinstein Weizmann Institute of Science
Edna Mozes
Edna Mozes Weizmann Institute of Science
Michel Revel
Michel Revel Weizmann Institute of Science
Yoram Reiter
Yoram Reiter Technion – Israel Institute of Technology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Immunology opens doors to various healthcare and research careers, often requiring specialized advanced degrees. For those interested in nursing roles linked to immune health, exploring the cheapest psych np programs online can be a cost-effective way to start a nurse practitioner career focused on mental health and immune system interactions.

A Doctorate in Nursing Practice (DNP) offers higher earning potential and leadership opportunities in immunology-related nursing. Understanding the doctorate in nursing salary by state helps prospective students evaluate the return on investment for such programs while considering job markets and cost living.

Nurses looking to specialize further can benefit from programs that facilitate taking their Family Nurse Practitioner (FNP) certification to the next level. The fnp to acute care certification process is essential for those aiming to work with patients in more complex immunology or acute care settings.

Additionally, accelerated pathways such as an accelerated fnp program offer a faster track to becoming qualified as a nurse practitioner. These programs are ideal for individuals with prior healthcare education who want to quickly pivot into immunology-focused specialties.

Best Scientists Citing Zelig Eshhar

Trending Scientists

Recently Published Articles